Antibody therapy represents one of the most promising and actively pursued therapeutic approaches for neurodegenerative diseases. This class of biologics leverages the specificity of the immune system to target pathological proteins, modulate cellular pathways, and potentially halt or slow disease progression in conditions such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and related disorders[@pmid34220465] PMID: 34220465. The development of [monoclonal antibodies](/therapeutics/monoclonal-antibodies) as therapeutics has revolutionized modern medicine, with the first therapeutic monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) in 1986 PMID: 2684164. Since then, over 100 [monoclonal antibodies](/therapeutics/monoclonal-antibodies) have received regulatory approval for various indications, and their application has expanded beyond oncology and autoimmune diseases into the field of neuroscience[@pmid35867012] PMID: 35867012.
Antibody therapy represents one of the most promising and actively pursued therapeutic approaches for neurodegenerative diseases. This class of biologics leverages the specificity of the immune system to target pathological proteins, modulate cellular pathways, and potentially halt or slow disease progression in conditions such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and related disorders[@pmid34220465] PMID: 34220465. The development of [monoclonal antibodies](/therapeutics/monoclonal-antibodies) as therapeutics has revolutionized modern medicine, with the first therapeutic monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) in 1986 PMID: 2684164. Since then, over 100 [monoclonal antibodies](/therapeutics/monoclonal-antibodies) have received regulatory approval for various indications, and their application has expanded beyond oncology and autoimmune diseases into the field of neuroscience[@pmid35867012] PMID: 35867012.
Neurodegenerative diseases share common pathophysiological features, including the accumulation of misfolded proteins, [neuroinflammation](/mechanisms/neuroinflammation), [synaptic dysfunction](/mechanisms/synaptic-dysfunction), and progressive [neuronal loss](/cell-types/neurons). Antibody-based therapies aim to address these mechanisms through several approaches: directly targeting and neutralizing pathogenic proteins, enhancing their clearance, or modulating the immune response to create a more favorable [central nervous system](/brain-regions/central-nervous-system) (CNS) environment[@pmid35658842] PMID: 35658842. The therapeutic potential of antibodies stems from their high affinity and specificity for their targets, which theoretically allows for precise intervention in disease processes while minimizing off-target effects.
The development of antibody therapies for neurodegeneration has accelerated dramatically over the past two decades, driven by advances in antibody engineering, a deeper understanding of disease biology, and the urgent unmet medical need represented by these conditions. Despite significant challenges, including the difficulty of delivering therapeutic antibodies across the [blood-brain barrier](/mechanisms/blood-brain-barrier) (BBB), several antibody therapies have now received regulatory approval, marking a new era in the treatment of neurodegenerative diseases PMID: 37352023.
The concept of using antibodies as therapeutic agents dates back to the late 19th century when Emil von Behring discovered that antibodies could neutralize toxins PMID: 11844851. However, the modern era of monoclonal antibody therapy began in 1975 when Georges Köhler and César Milstein developed hybridoma technology, enabling the production of antibodies with defined specificity PMID: 4630588. This breakthrough earned them the Nobel Prize in Physiology or Medicine in 1984 and paved the way for the development of therapeutic [monoclonal antibodies](/therapeutics/monoclonal-antibodies).
The first therapeutic [monoclonal antibodies](/therapeutics/monoclonal-antibodies) were murine-based, but their clinical use was limited by human anti-mouse antibody (HAMA) responses that reduced efficacy and caused serum sickness-like reactions PMID: 1645306. The development of chimeric antibodies, in which the variable regions of murine antibodies are fused to human constant regions, reduced immunogenicity while maintaining target specificity PMID: 2676281. Further advances led to humanized antibodies, which contain only complementarity-determining regions (CDRs) from murine sources, and fully human antibodies generated through phage display or transgenic mouse technologies PMID: 2190392.
Therapeutic antibodies have evolved considerably beyond the standard immunoglobulin G ([IgG](/proteins/igg)) format. Various antibody engineering strategies have been employed to enhance efficacy, improve pharmacokinetics, or reduce costs PMID: 33741711. Key antibody formats include:
Fragment antigens binding (Fab) fragments consist of the variable regions of the heavy and light chains connected by a disulfide bond. These smaller fragments (approximately 50 kDa) have faster clearance from circulation but may have reduced efficacy due to shorter half-life and lack of [Fc](/proteins/fc-receptor)-mediated effector functions.
Single-chain variable fragments (scFv) contain only the variable regions linked by a flexible peptide. At approximately 25 kDa, these are even smaller than Fab fragments but may have reduced binding affinity due to the absence of the full antigen-binding site.
Bispecific antibodies are engineered to recognize two different antigens simultaneously, enabling novel therapeutic mechanisms such as redirecting T cells to tumor cells or simultaneously targeting two pathogenic proteins PMID: 31737537.
Fc-engineered antibodies have modified [Fc](/proteins/fc-receptor) regions that alter binding to [Fc](/proteins/fc-receptor) receptors, potentially enhancing efficacy, reducing side effects, or extending half-life through engineered glycoengineering PMID: 31781666.
The identification of specific protein aggregates as central to neurodegeneration has enabled the rational design of antibody therapies. The major targets include [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and emerging targets such as [TREM2](/proteins/trem2).
[Amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides are derived from the [amyloid precursor protein](/proteins/amyloid-precursor-protein) (APP) through sequential proteolytic cleavage by β- and γ-secretases. The aggregation of Aβ into soluble oligomers and insoluble plaques has long been considered a initiating event in [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis PMID: 12563030. This "amyloid hypothesis" has driven extensive drug development efforts targeting Aβ, including antibody-based approaches.
Aβ-directed antibodies aim to reduce cerebral amyloid burden through several mechanisms: binding to soluble Aβ and preventing aggregation, promoting clearance of existing plaques via Fc-mediated [microglia](/cell-types/microglia)l phagocytosis, or neutralizing toxic oligomeric species PMID: 25921056. Several Aβ antibodies have advanced to late-stage clinical trials, with mixed results.
Aducanumab (Aduhelm) is a human [IgG](/proteins/igg)1 antibody that selectively targets aggregated Aβ, including both soluble oligomers and insoluble plaques. The EMERGE and ENGAGE Phase 3 trials initially failed to meet their primary endpoints in 2019, but subsequent analysis of expanded datasets revealed reduced clinical decline in patients receiving high-dose aducanumab, accompanied by significant reduction in amyloid plaque burden PMID: 33148843. Based on these results, aducanumab received accelerated approval from the FDA in 2021, making it the first disease-modifying therapy for [Alzheimer's disease](/diseases/alzheimers-disease) PMID: 34552062. However, the approval remained controversial due to conflicting trial results, and the European Medicines Agency (EMA) rejected its authorization.
Lecanemab (Leqembi) is a humanized [IgG](/proteins/igg)1 antibody that binds with high affinity to Aβ protofibrils, considered the most toxic form of Aβ. The CLARITY-AD Phase 3 trial demonstrated that lecanemab significantly reduced clinical decline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) compared to placebo at 18 months, with a 27% reduction in cognitive decline PMID: 36449457. Lecanemab received full FDA approval in 2023, representing the first confirmation of clinical benefit in an anti-amyloid antibody. However, ARIA (amyloid-related imaging abnormalities) representing brain edema and hemorrhage occurred in approximately 21% of participants, requiring careful monitoring.
Donanemab is a humanized [IgG](/proteins/igg)1 antibody targeting a specific form of modified Aβ (pyroglutamate Aβ). The TRAILBLAZE-ALZ Phase 3 trial demonstrated that donanemab significantly slowed clinical progression, with 35% slower decline on iADRS (integrated Alzheimer's Disease Rating Scale) compared to placebo PMID: 37352023. Based on these results, donanemab received FDA approval in 2024. Like other anti-amyloid antibodies, ARIA was observed in approximately 37% of treated patients.
Gantenerumab is a fully human [IgG](/proteins/igg)1 antibody that binds to both monomeric and aggregated Aβ. Despite showing amyloid reduction in the open-label GRADIENT extension study, the SCarlet RoAD and Marguerite RoAD Phase 3 trials failed to meet their primary endpoints, and development was discontinued PMID: 26235533.
Solanezumab is a humanized [IgG](/proteins/igg)1 antibody that binds to the mid-domain of Aβ, primarily targeting soluble monomeric Aβ. The EXPEDITION Phase 3 trials in mild-to-moderate AD failed to demonstrate cognitive benefit, and development was discontinued PMID: 25041470.
[Tau](/proteins/tau) proteins are microtubule-associated proteins that stabilize [neuronal](/cell-types/neurons) axons. In [Alzheimer's disease](/diseases/alzheimers-disease) and other [tauopathies](/diseases/progressive-supranuclear-palsy), [tau](/proteins/tau) becomes hyperphosphorylated, misfolds, and aggregates into [neurofibrillary tangles](/diseases/alzheimers-disease#neurofibrillary-tangles) (NFTs) that correlate closely with cognitive decline PMID: 12563028. [Tau](/proteins/tau) pathology spreads prion-like through neural circuits, and targeting [tau](/proteins/tau) with antibodies has emerged as a complementary strategy to anti-amyloid therapies PMID: 28653647.
Anti-[tau](/proteins/tau) antibodies aim to prevent [tau](/proteins/tau) aggregation, promote clearance of existing tangles, or block the intercellular spread of pathological [tau](/proteins/tau). Several antibodies have advanced to clinical development, with mixed results.
LMTM (Lademirsen) is an antisense oligonucleotide rather than an antibody, but anti-[tau](/proteins/tau) antibodies have included several candidates. Gantenerumab, mentioned above for its anti-amyloid activity, also binds to [tau](/proteins/tau) aggregates and has been studied in primary [tauopathies](/diseases/progressive-supranuclear-palsy). The TAURIEL trial evaluated gantenerumab in patients with mild cognitive impairment due to [Alzheimer's disease](/diseases/alzheimers-disease), but primary endpoints were not met PMID: 33067454.
ABBV-8E12 (Cinomerersen) is a humanized [IgG](/proteins/igg)4 antibody targeting extracellular [tau](/proteins/tau). A Phase 2 trial in [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP) showed acceptable safety but did not meet its primary endpoint of slowing clinical decline PMID: 33408464.
JNJ-63733657 is a fully human anti-[tau](/proteins/tau) [IgG](/proteins/igg)4 antibody that binds to phosphorylated [tau](/proteins/tau). A Phase 1 study demonstrated target engagement and acceptable safety, supporting further development PMID: 35085352.
Semorinemab is a humanized [IgG](/proteins/igg)4 antibody that binds to the N-terminal region of [tau](/proteins/tau). The Lauriet trial in moderate AD failed to meet its primary endpoint of reducing cognitive decline, though some secondary endpoints showed potential benefit PMID: 36653511.
[Alpha-synuclein](/proteins/alpha-synuclein) is a presynaptic protein that aggregates into Lewy bodies in [Parkinson's disease](/diseases/parkinsons-disease) and related disorders. The prion-like spread of [alpha-synuclein](/proteins/alpha-synuclein) pathology throughout the brain is thought to underlie disease progression PMID: 18986257. Antibodies targeting [alpha-synuclein](/proteins/alpha-synuclein) aim to neutralize extracellular [alpha-synuclein](/proteins/alpha-synuclein) aggregates, prevent [neuronal](/cell-types/neurons) uptake, and potentially slow disease progression.
Prasinezumab (PRX002) is a humanized [IgG](/proteins/igg)1 antibody that binds to the C-terminus of [alpha-synuclein](/proteins/alpha-synuclein). The PASADENA Phase 2 trial in early [Parkinson's disease](/diseases/parkinsons-disease) met its primary endpoint of safety and tolerability, and although clinical outcomes did not reach statistical significance at the primary analysis, longer-term follow-up suggested potential disease-modifying effects PMID: 34927027.
Cinomerersen (BIIB054) is a fully human [IgG](/proteins/igg)1 antibody that binds to [alpha-synuclein](/proteins/alpha-synuclein) and inhibits its aggregation. The SPARK Phase 2 trial in [Parkinson's disease](/diseases/parkinsons-disease) did not meet its primary endpoint of reducing clinical decline, though biomarker analyses suggested target engagement PMID: 35484277.
APO-810 (WVE-004) is an antibody designed to target pathological [alpha-synuclein](/proteins/alpha-synuclein) aggregates. Phase 1 studies are ongoing in [multiple system atrophy](/diseases/multiple-system-atrophy) (MSA), a rapidly progressive synucleinopathy PMID: 36708353.
[Triggering receptor expressed on myeloid cells 2](/proteins/trem2) (TREM2) is a cell surface receptor expressed on [microglia](/cell-types/microglia) that plays a critical role in [neuroinflammation](/mechanisms/neuroinflammation) and amyloid clearance. Rare coding variants in [TREM2](/proteins/trem2) increase the risk of [Alzheimer's disease](/diseases/alzheimers-disease) approximately three-fold, highlighting its importance in disease pathogenesis PMID: 23999529. [Microglial](/cell-types/microglia) dysfunction contributes to neurodegeneration, and targeting [TREM2](/proteins/trem2) represents a novel therapeutic strategy.
AL002 (ALX0681) is a humanized [IgG](/proteins/igg)1 antibody that activates [TREM2](/proteins/trem2) signaling. Phase 1 studies demonstrated acceptable safety and evidence of target engagement in the [central nervous system](/brain-regions/central-nervous-system), supporting advancement to Phase 2 trials in early [Alzheimer's disease](/diseases/alzheimers-disease) PMID: 36734265.
SHT-305 is another [TREM2](/proteins/trem2)-targeting antibody that entered clinical development but has shown limited public disclosure of results.
Other [microglial](/cell-types/microglia) targets under investigation include CD33, where genetic variants influence AD risk, and CSF1R, which modulates [microglia](/cell-types/microglia)l survival and function PMID: 32877961.
Beyond the major protein aggregates, antibody therapies are being developed against several other targets:
[Apolipoprotein E](/proteins/apolipoprotein-e) (ApoE) polymorphisms, particularly the ε4 allele, represent the strongest genetic risk factor for late-onset AD. antibodies targeting [ApoE4](/proteins/apolipoprotein-e) are being developed to reduce its pathogenic effects on amyloid deposition and [neuroinflammation](/mechanisms/neuroinflammation) PMID: 29488665.
Alpha-1 antichymotrypsin (ACT) is an acute-phase protein that co-deposits with Aβ plaques and may accelerate aggregation. Antibodies targeting ACT are in preclinical development.
N-terminal pyroglutamate Aβ is a particularly neurotoxic modified form of Aβ that is found in early plaque deposits. Several antibodies targeting this modification have entered clinical trials.
Antibody therapies for neurodegeneration employ multiple mechanisms to exert their therapeutic effects. Understanding these mechanisms is crucial for optimizing drug design and predicting clinical outcomes.
The most straightforward mechanism involves antibodies binding to their target protein, thereby neutralizing its pathological activity. For extracellular proteins like soluble [Aβ](/proteins/amyloid-beta) oligomers, this binding can prevent interactions with [neuronal](/cell-types/neurons) receptors, block aggregation, or simply sequester the protein in a form that cannot penetrate cells PMID: 25282378.
For intracellular targets, antibodies must either enter cells or act on extracellular domains of membrane-bound proteins. Intracellular delivery of antibodies remains challenging, though innovative approaches such as engineered toxin fragments or viral vectors are being explored.
When antibodies bind to their targets, the [Fc](/proteins/fc-receptor) region can engage [Fc](/proteins/fc-receptor) receptors (FcγRs) on immune cells, particularly [microglia](/cell-types/microglia) in the [central nervous system](/brain-regions/central-nervous-system). This engagement can trigger several protective mechanisms:
Phagocytosis (antibody-dependent cellular phagocytosis, ADCP): Fc-engaged [microglia](/cell-types/microglia) can engulf and destroy antibody-coated targets, including amyloid plaques. This mechanism likely contributes significantly to the amyloid-reducing effects observed with aducanumab, lecanemab, and donanemab PMID: 31745706.
Complement activation can lead to target cell lysis through the membrane attack complex (MAC). However, complement activation in the brain may contribute to inflammatory side effects, and antibody engineering to modulate [Fc](/proteins/fc-receptor) effector function is an active area of research.
Antibody-dependent cellular cytotoxicity (ADCC) involves natural killer (NK) cells and other cytotoxic cells recognizing Fc-bound targets. The relative importance of ADCC in the [central nervous system](/brain-regions/central-nervous-system) compared to peripheral tissues is unclear.
Beyond directly clearing pathological proteins, antibodies can modulate the immune environment in ways that may be beneficial in neurodegeneration. For example, anti-Aβ antibodies may reduce [neuroinflammation](/mechanisms/neuroinflammation) by decreasing the load of pro-inflammatory aggregates, or [TREM2](/proteins/trem2)-activating antibodies may shift [microglia](/cell-types/microglia) toward a protective phenotype PMID: 35550260.